Editorial Information
Meet the Editorial Advisory Board
![]() |
Meet the PharmaAsia Editors |
![]() |
Meet the Editorial Advisory Board |
![]() |
Contribution Guidelines |
![]() |
Michael Tham |
| Editor michael.tham@rbi-asia.com |
|
Prior to joining PharmaAsia, Michael Tham managed editorial teams for a technology-based trade publication. He was formerly a project manager in software systems for the medical industry. He previously served as a lecturer at the Curtin University of Technology in Perth, Australia. |
Meet the Editorial Advisory Board
![]() |
Eize de Boer, PhD |
Global Manager, Life Science Auditing |
|
| Since joining SGS in 2007, Dr. de Boer oversees the creation and project management of second- and third-party auditing programs to support SGS’ quality management offering for the pharmaceutical industry. Previously, Dr. de Boer served as site director for Wyeth, which he joined in 1997. He was responsible for manufacturing and supply chain operations, including the development and maintenance of a wide variety of pharmaceutical quality management systems. He holds a PhD in biochemistry from the University of Amsterdam, The Netherlands. |
![]() |
Ian Griffiths |
| Medical Director GSK International Medical, Asia Pacific |
|
| Griffiths has been employed in GSK's Pharmaceutical Research & Development for the past 11 years and is based in Singapore. His present role at GSK focuses on clinical research with an emphasis on the effective delivery of early and late phase clinical trail data. His personal focus is on cardiovascular outcomes studies, diabetes and autoimmune disease. His area office oversees research in all therapy areas, stage I through to IV. The corollary of this research role is to ensure that the data generated is interpreted correctly into both regulatory documents and medical marketing messages. This encompasses medical governance oversight in the larger organization. Griffiths is a graduate of the University of Otago Medical School, New Zealand and is a distinguished Fellow of the RNZCGP. |
![]() |
Jasmin Patel, PhD |
| Managing Director, Fidelity Ventures | |
| Jasmin Patel is previously the chief operating officer for the Indian pharma business of leading MNC Novartis. He was responsible for the set up and development of a new pharma business in India and which was expected to be the Launch Engine for select novel products from the Novartis pipeline. Prior to assuming these responsibilities Patel was the Head of Disease Area Strategy and M&A Assessments for two years at Novartis global headquarters in Basel. [More] |
![]() |
Jerold Martin, MSc |
| Senior Vice President, Scientific Affairs Pall Life Sciences |
|
| At Pall Life Sciences, Martin is responsible for technical and regulatory communications. He has over 30 years experience in biopharmaceutical filtration and separation technologies including validation, technical services, research and development, and marketing. Martin is director and technology committee chair with the BioProcess Systems Alliance (BPSA), where he has recently co-authored the BPSA Guides to Component Quality Tests, Irradiation and Sterilization, and Extractables and Leachables from Single-use Systems for biomanufacturing. He is on advisory boards of Parenteral Drug Association (PDA) and magazines such as Genetic Engineering News and Pharmaceutical Technology Europe. He holds an MSc in Microbiology from the University of Toronto. |
![]() |
Lee E. Babiss, PhD |
President & Global Head, Pharma Research |
|
| Lee E. Babiss, PhD, is previously the vice president of Preclinical Research and Development for Roche, in Nutley, New Jersey, where he developed and directed oncology and metabolic diseases research strategy for the site. In addition, Babiss is a member of the International Research Management Team, which develops the company’s global research strategy and is the chair of the Roche Biomarker Leadership Team, which oversees a cross-divisional effort within the company’s pharmaceuticals and diagnostics divisions aimed at developing and implementing a biomarker strategy. [More] |
![]() |
Rama Shankar |
| Quality Performance Manager TAP Pharmaceutical Products Inc. |
|
| Rama Shankar focuses on setting up Quality Management Systems, increasing productivity, improving cycle time, quality, and eliminating waste within strategic processes. Rama holds an M.S. in Engineering Management from Northwestern University, Evanston, IL, and a B.S. in Mechanical Engineering from India. She is a Certified Six Sigma Black Belt, Certified Quality Auditor, Malcolm Baldridge Award Examiner and a certified Lean Trainer. She is also an adjunct professor at Illinois Institute of Technology, Chicago, IL. |
![]() |
Shama M. Kajiji, Ph.D. MBA |
| Director, Portfolio Franchise Management Department Merck & Co |
|
| Shama Kajiji’s drug discovery and development experience encompasses small molecules and human antibodies, some of which successfully progressed to Phase 3 studies. She is listed as a co-inventor on 10 patents and has published extensively in peer-reviewed journals. In order to better integrate the business and scientific objectives of the company, she completed an Executive MBA from the University of Rhode Island in 1998. This business training plus her Discovery - Development experience with in-house candidates and external licensing opportunities prepared her for taking on the previous role of leading the Attrition Analysis Office at Pfizer.
[More] |





















